Acetylleucine - IntraBio
Alternative Names: Acetyl-DL-leucine - IntaBio; Acetyl-leucine - IntraBio; IB 1000; IBI1000; N-Acetyl-DL-leucine - IntraBioLatest Information Update: 24 Mar 2021
At a glance
- Originator University of Munich; University of Oxford
- Developer IntraBio
- Class Acetamides; Amino acids; Esters; Pentanoic acids; Small molecules; Vestibular disorder therapies
- Mechanism of Action Calcium channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II/III Ataxia
- Phase II Niemann-Pick disease type C; Tay-Sachs disease
Most Recent Events
- 24 Mar 2021 Phase-II development is ongoing for Niemann-Pick disease type C in United Kingdom (IntraBio pipeline, March 2021)
- 24 Mar 2021 Phase-II development is ongoing for Tay-Sachs disease in United Kingdom (IntraBio pipeline, March 2021)
- 24 Mar 2021 Phase-II/III development is ongoing for Ataxia in United Kingdom (IntraBio pipeline, March 2021)